MiMedx details $350M Sanara deal alongside Q2 loss and reiterated guidance
MDXG sits 37% above its 52-week low of $3.025.
Summary
MiMedx posted a Q2 net loss of $15 million on sales of $64 million, reaffirmed its 2026 outlook, and announced a definitive agreement to acquire Sanara MedTech for $350 million in cash and stock, creating a surgical-focused company with over $400 million in combined revenue.
Key Events · Earnings and Guidance · MDXG
-
Q2 Revenue Plunges 35% on Wound Weakness
Net sales fell to $64 million from $99 million a year ago, as Wound sales dropped 61% due to Medicare reimbursement changes. Surgical sales grew 15% to $39 million.
-
Swings to $15M Net Loss
GAAP net loss was $15 million vs. a $10 million profit last year. Adjusted EBITDA was -$8 million, with gross margin compressing to 69% from 81%.
-
Reiterates 2026 Guidance
Management reaffirmed full-year net sales of $260–290 million and expects Adjusted EBITDA to approach breakeven, implying a significant second-half ramp.
-
Acquires Sanara MedTech for $350M
MiMedx will pay $35 per Sanara share — $33 in cash and 0.4735 MDXG shares — in a deal valued at ~$350 million. The transaction adds >$100 million in surgical revenue and is expected to close by year-end 2026.
Analysis · MDXG · Industrial Applications And Services
A 35% revenue drop to $64 million and a swing to a $15 million GAAP net loss underscore the damage from Medicare reimbursement cuts to the Wound business. Surgical sales provided a counterpoint, rising 15%. The full-year sales outlook of $260–290 million was reaffirmed, with Adjusted EBITDA expected to approach breakeven. The defining move, however, is the definitive agreement to acquire Sanara MedTech for $350 million in cash and stock—a transaction that pivots MiMedx toward a surgical focus. It brings over $100 million in surgical revenue, targets a year-end close, and is backed by a new $300 million term loan. On a combined basis, management sees revenue well above $400 million, Adjusted EBITDA margins exceeding 20%, and $20 million in cost synergies. While transformative, the deal layers on execution risk and leverage at a time when the core Wound franchise remains under severe reimbursement pressure.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXG was trading at $4.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.